Johnson & Johnson reports early-stage prostate cancer drug trial response
Johnson & Johnson says its experimental once-daily oral prostate cancer treatment shows tumor shrinkage or disappearance in an early-stage study of patients with advanced disease. The candidate, JNJ-6143, expands the drugmaker's prostate cancer pipeline after the company gained access to it through its $3.05 billion Halda Therapeutics deal last year.
Highlights
- Johnson & Johnson's JNJ-6143 trial shows 77% of 31 patients had PSA drops of at least 50%, with 69% imaging response rate.
- Side effects of JNJ-6143 include nausea and elevated cholesterol or triglycerides, causing one discontinuation among trial participants.
- JNJ-6143, acquired via Johnson & Johnson's $3.05 billion Halda Therapeutics deal, broadens its oncology pipeline in the prostate cancer market.
Trial results and treatment profile
As reported by Reuters, Johnson & Johnson says it is testing JNJ-6143 in patients with advanced prostate cancer who have received multiple prior treatments, with new data presented at the European Society for Medical Oncology Congress.In the trial, 77% of 31 evaluable patients receiving the 50-milligram dose saw their PSA levels fall by at least 50%. In 48% of patients, PSA levels fell by at least 90%, while 69% of patients whose tumors could be measured on imaging had a confirmed complete or partial response.
The company says the drug uses a novel approach that selectively kills cancer cells by interfering with a protein they need to survive. Common side effects are nausea and elevated cholesterol and triglyceride levels, and one patient discontinues treatment because of adverse effects.
Portfolio significance for Johnson & Johnson
JNJ-6143 adds another potential mechanism of action to Johnson & Johnson's prostate cancer portfolio, according to a company spokesperson. The update points to how the group is using acquired assets to broaden its oncology pipeline in a highly competitive cancer treatment market.Johnson & Johnson gained access to the drug through its $3.05 billion acquisition of Halda Therapeutics last year. The early-stage data do not establish late-stage efficacy, but they provide an initial signal the company can use to support further development in advanced prostate cancer.
Our earlier article on AstraZeneca’s AI drug-discovery collaboration with insitro highlighted the company’s push to use machine learning to improve target selection in tough disease areas like MASH and cardiomyopathies. We noted that insitro’s “Virtual Human” platform is designed to move AstraZeneca-nominated targets from discovery to development-candidate stage, while AstraZeneca would fund and run any future clinical trials under the agreement.
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
